Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Lilly

Experts weigh in on Labour plan to offer weight loss jabs to unemployed

LABOUR plans to give obese and unemployed people weight-loss jabs as part of a drive to get them back into work and reduce pressure on the NHS…

The National (Scotland)

Hims & Hers Shares Rallied 22% Over Two Days. Why That Move Is Now At Risk.

Hims & Hers Shares Rallied 22% Over Two Days. Why That Move Is Now At Risk.

Hims stock rallied almost 22% over two days on enthusiasm after the FDA said it will allow compounded versions of Lilly's obesity drug.

Investors Business Daily

Unemployed to be given weight-loss jags as part of UK plan to 'get them back to work'

Unemployed to be given weight-loss jags as part of UK plan to 'get them back to work'

THE Health Secretary has said unemployed people will be given weight-loss injections as part of a UK Government drive to “get them back to…

The National (Scotland)

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug

Hims stock popped Monday after the FDA reportedly said it would reconsider its decision to bar compounders from selling knockoff tirzepatide.

Investors Business Daily

Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade

Amgen stock dipped Monday after an analyst downgraded shares, saying the opportunity for its weight-loss drug is already baked into the stock.

Investors Business Daily

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer

Viking Therapeutics stock is on the rise as the battle to develop new weight-loss drugs heats up. Here's what's at stake for the pharma giants fighting for position.

Investors Business Daily

Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.

Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Meet the 9 CFOs on Fortune’s 2024 Most Powerful Women list

Meet the 9 CFOs on Fortune’s 2024 Most Powerful Women list

The list of 100 executives spans the globe.

BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rises On Upsized IPO

BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rises On Upsized IPO

BioAge Labs stock rose Thursday on the company's upsized IPO — reflecting enthusiasm for its approach to obesity treatments.

Investors Business Daily

Is Eli Lilly Stock Still a Buy Near All-Time Highs?

Is Eli Lilly Stock Still a Buy Near All-Time Highs?

With a robust performance, strategic expansions, and strong analyst endorsements, Eli Lilly appears poised for continued growth, making it a compelling investment opportunity.

Snag This Biotech Stock Before November, Here's Why

Snag This Biotech Stock Before November, Here's Why

With Viking Therapeutics making a splash in the weight-loss drug arena, one analyst is encouraging investors to snap up the stock before a November catalyst.

Eli Lilly's new CFO is a 23-year company veteran—showing how pharma firms rely on a 'deep bench of qualified talent'

Eli Lilly's new CFO is a 23-year company veteran—showing how pharma firms rely on a 'deep bench of qualified talent'

Lucas Montarce's career path at the company is similar to that of his predecessor, Anat Ashkenazi.

Eli Lilly Names New CFO Amid Weight-loss Drug Expansion Plan

Eli Lilly Names New CFO Amid Weight-loss Drug Expansion Plan

U.S. pharmaceutical giant Eli Lilly named a new chief financial officer on Monday during a critical time for the company's exploding weight-loss drug market.

International Business Times

How Lilly, Novo Could Beat Tesla To The Trillion-Dollar Club; Plus, Nvidia's Battle With Microsoft, Apple

How Lilly, Novo Could Beat Tesla To The Trillion-Dollar Club; Plus, Nvidia's Battle With Microsoft, Apple

Weight-loss drug kingpins Eli Lilly and Novo Nordisk could join the trillion-dollar company club before even Tesla, according to a report.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

How Is Eli Lilly’s Stock Performance Compared to Other Drug Manufacturer Stocks?

Eli Lilly has recently outperformed the general drug manufacturers industry, and analysts are highly optimistic about the stock’s prospects.

Former Maryland Resident Sentenced For Congressional Office Harassment

Former Maryland resident sentenced to prison for making threatening calls to congressional offices, highlighting the seriousness of threats against elected...

The Independent UK

Man sentenced to over 1 year in prison for thousands of harassing calls to congressional offices

A former Maryland resident has been sentenced to more than one year behind bars for making thousands of threatening and harassing telephone calls to dozens of congressional offices across the country

Investors Business Daily

S&P 500 Giants Meta, Eli Lilly Lead 5 Stocks Near Buy Points

Meta, Costco and Eli Lilly along with two others are trading near buy points coming out of a week marked by Nvidia earnings.

Get all your
news in one place.

100’s of premium titles.
One news app.

3 Mega-Cap Stocks Not Named Nvidia Up More than 40% in 2024

Shares of mega-cap stocks such as Walmart, Meta Platforms, and Eli Lilly have surged over 40% in 2024, outpacing the broader markets by a wide margin.

Investors Business Daily

The 10 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race

The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.

Investors Business Daily

Eli Lilly Option Trade Could Return $1,650, If Stock Doesn't Go Haywire

The idea with the trade is that if Eli Lilly stock remains around 950 for the next few weeks, the sold option will decay faster than the bought option.

International Business Times

Eli Lilly Launches Discount Anti-Obesity Drug

The company claims the Zepbound doses cost 50% less than competing drugs

Investors Business Daily

Eli Lilly, An IBD 50 Stock, Nears Record High On Another Weight-Loss Win

Eli Lilly stock rose Tuesday after Lilly's weight-loss drug significantly cut the risk of developing diabetes over three years.

Up 58% YTD, is Eli Lilly Stock Still a Buy?

The pharmaceutical giant has already delivered massive gains this year, but Wall Street analysts have only gotten more bullish on the maker of Mounjaro and Zepbound.

Investors Business Daily

Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review

Monday's global sell-off turned into a stock market rally attempt. Palantir, Eli Lilly and Fortinet were among the earnings winners.

People

Mark Zuckerberg

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

the UK Government

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

264,740 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play